A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Linch, Mark ^a   Gennatas, Spyridon ^a   Kazikin, Stanislav ^a   Iqbal, Jhangir ^a   Gunapala, Ranga ^a   Priest, Kathryn ^a   Severn, Joanne ^a   Norton, Alison ^a   Ayite, Bee ^a   Bhosle, Jaishree ^a   O'Brien, Mary ^a   Popat, Sanjay ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Biomarker; Mesothelin; Prognosis; Response

Indexed keywords

BORTEZOMIB; CISPLATIN; MESOTHELIN; MITOMYCIN; PEMETREXED; RALTITREXED; VINBLASTINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPLORATORY RESEARCH; FEMALE; HUMAN; KRUSKAL WALLIS TEST; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; TREATMENT RESPONSE; VERY ELDERLY; YOUNG ADULT; BLOOD; LUNG NEOPLASMS; MESOTHELIOMA; MIDDLE AGED; MORTALITY; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GPI-LINKED PROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84908135474     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-674     Document Type: Article

References (36)

1. Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005, 92(3):587-593. 2362088, 15668716.
2. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005, 353(15):1591-1603. 10.1056/NEJMra050152, 16221782.
3. Burt BM, Bader A, Winter D, Rodig SJ, Bueno R, Sugarbaker DJ. Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation. Clin Cancer Res 2012, 18(6):1568-1577. 10.1158/1078-0432.CCR-11-1808, 22261806.
4. Levallet G, Vaisse-Lesteven M, Le Stang N, Ilg AG, Brochard P, Astoul P, Pairon JC, Bergot E, Zalcman G, Galateau-Salle F. Plasma cell membrane localization of c-MET predicts longer survival in patients with malignant mesothelioma: a series of 157 cases from the MESOPATH Group. J Thorac Oncol 2012, 7(3):599-606. 10.1097/JTO.0b013e3182417da5, 22246193.
5. Kao SC, Armstrong N, Condon B, Griggs K, McCaughan B, Maltby S, Wilson A, Henderson DW, Klebe S. Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma. Cancer 2012, 118(11):2952-2961. 10.1002/cncr.26497, 22020536.
6. Kao SC, Klebe S, Henderson DW, Reid G, Chatfield M, Armstrong NJ, Yan TD, Vardy J, Clarke S, van Zandwijk N, McCaughan B. Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. J Thorac Oncol 2011, 6(11):1923-1929. 10.1097/JTO.0b013e31822a3740, 22011651.
7. Baldi A, Mottolese M, Vincenzi B, Campioni M, Mellone P, Di Marino M, di Crescenzo VG, Visca P, Menegozzo S, Spugnini EP, Citro G, Ceribelli A, Mirri A, Chein J, Shridhar V, Ehrmann M, Santini M, Facciolo F. The serine protease HtrA1 is a novel prognostic factor for human mesothelioma. Pharmacogenomics 2008, 9(8):1069-1077. 10.2217/14622416.9.8.1069, 18681782.
8. Plathow C, Klopp M, Thieke C, Herth F, Thomas A, Schmaehl A, Zuna I, Kauczor HU. Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT. Eur Radiol 2008, 18(8):1635-1643. 10.1007/s00330-008-0918-9, 18369634.
9. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004, 15(2):257-260. 10.1093/annonc/mdh059, 14760119.
10. Steele JP, Klabatsa A, Fennell DA, Pallaska A, Sheaff MT, Evans MT, Shamash J, Rudd RM. Prognostic factors in mesothelioma. Lung Cancer 2005, 49(Suppl 1):S49-S52.
11. Ghanim B, Hoda MA, Winter MP, Klikovits T, Alimohammadi A, Hegedus B, Dome B, Grusch M, Arns M, Schenk P, Pohl W, Zielinski C, Filipits M, Klepetko W, Berger W. Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis. Ann Surg 2012, 256(2):357-362. 10.1097/SLA.0b013e3182602af4, 22750759.
12. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998, 113(3):723-731. 10.1378/chest.113.3.723, 9515850.
13. Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Gregoire M, Porte H, Copin MC, Lassalle P. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007, 13(10):2928-2935. 10.1158/1078-0432.CCR-06-2144, 17504993.
14. Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, Huflejt M, Carbone M, Chia D, Goodglick L, Goodman GE, Thornquist MD, Liu G, de Perrot M, Tsao MS, Goparaju C. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 2012, 367(15):1417-1427. 10.1056/NEJMoa1115050, 3761217, 23050525.
15. Cristaudo A, Foddis R, Vivaldi A, Guglielmi G, Dipalma N, Filiberti R, Neri M, Ceppi M, Paganuzzi M, Ivaldi GP, Mencoboni M, Canessa PA, Ambrosino N, Chella A, Mutti L, Puntoni R. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007, 13(17):5076-5081. 10.1158/1078-0432.CCR-07-0629, 17785560.
16. Beyer HL, Geschwindt RD, Glover CL, Tran L, Hellstrom I, Hellstrom KE, Miller MC, Verch T, Allard WJ, Pass HI, Sardesai NY. MESOMARK: a potential test for malignant pleural mesothelioma. Clin Chem 2007, 53(4):666-672. 10.1373/clinchem.2006.079327, 17289801.
17. Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008, 85(1):265-272. discussion 272, 10.1016/j.athoracsur.2007.07.042, 18154821.
18. Pantazopoulos I, Boura P, Xanthos T, Syrigos K. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma. Eur Respir J 2013, 41(3):706-715. 10.1183/09031936.00226111, 22835614.
19. Wang K, Bodempudi V, Liu Z, Borrego-Diaz E, Yamoutpoor F, Meyer A, Woo RA, Pan W, Dudek AZ, Olyaee MS, Esfandyari T, Farassati F. Inhibition of mesothelin as a novel strategy for targeting cancer cells. PLoS One 2012, 7(4):e33214. 10.1371/journal.pone.0033214, 3317639, 22485139.
20. Uehara N, Matsuoka Y, Tsubura A. Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells. Mol Cancer Res 2008, 6(2):186-193. 10.1158/1541-7786.MCR-07-0254, 18245228.
21. Kelly RJ, Sharon E, Pastan I, Hassan R. Mesothelin-targeted agents in clinical trials and in preclinical development. Mol Cancer Ther 2012, 11(3):517-525. 10.1158/1535-7163.MCT-11-0454, 3297681, 22351743.
22. Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, Leighl N, Feld R, Cho BC, O'Sullivan B, Roberts H, Tsao MS, Tammemagi M, Anraku M, Chen Z, de Perrot M, Liu G. Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol 2010, 28(20):3316-3322. 10.1200/JCO.2009.26.9944, 20498407.
23. Creaney J, Christansen H, Lake R, Musk AB, de Klerk N, Robinson BW. Soluble mesothelin related protein in mesothelioma. J Thorac Oncol 2006, 1(2):172-174. 10.1097/01243894-200602000-00013, 17409849.
24. Grigoriu BD, Chahine B, Vachani A, Gey T, Conti M, Sterman DH, Marchandise G, Porte H, Albelda SM, Scherpereel A. Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. Am J Respir Crit Care Med 2009, 179(10):950-954. 10.1164/rccm.200807-1125OC, 19201924.
25. Creaney J, Francis RJ, Dick IM, Musk AW, Robinson BW, Byrne MJ, Nowak AK. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Clin Cancer Res 2011, 17(5):1181-1189. 10.1158/1078-0432.CCR-10-1929, 21177406.
26. Middleton GW, Smith IE, O'Brien ME, Norton A, Hickish T, Priest K, Spencer L, Ashley S. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 1998, 9(3):269-273. 10.1023/A:1008236010868, 9602260.
27. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21(14):2636-2644. 10.1200/JCO.2003.11.136, 12860938.
28. Vogelzang N, Symanowski J, Rusthoven J, Manegold C, Boyer M, Nguyen B, Paoletti P. Long-term survival update from the randomized phase III study of pemetrexed plus cisplatin in patients with malignant pleural mesothelioma (MPM). Lung Cancer 2005, 49(2):S230-S231.
29. Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res 2010, 16(24):6132-6138. 10.1158/1078-0432.CCR-10-2275, 3057907, 21037025.
30. Rao C, Huber M, Vemuri K, Zhang Q, Chen B, Phillips J, Greenbaum M, Sung J, Derwin D, Passmore D, Vangipuram R, Terrett J, Deshpande S, Cardarelli P, Blanset D, Gangwar S. Abstract #3235: Efficacy and toxicity of an anti-mesothelin antibody drug conjugate. Proc 100th Annu Meet Am Assoc Canc Res 2009, 2:3235.
31. Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, Giedlin M, Louis JL, Sugar EA, Pons A, Cox AL, Levine J, Murphy AL, Illei P, Dubensky TW, Eiden JE, Jaffee EM, Laheru AD. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res 2012, 18(3):858-868. 10.1158/1078-0432.CCR-11-2121, 3289408, 22147941.
32. Colovos C, Villena-Vargas J, Adusumilli PS. Safety and stability of retrovirally transduced chimeric antigen receptor T cells. Immunotherapy 2012, 4(9):899-902. 10.2217/imt.12.91, 23046233.
33. Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, Predina J, Powell DJ, Riley JL, June CH, Albelda SM. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res 2011, 17(14):4719-4730. 10.1158/1078-0432.CCR-11-0351, 3612507, 21610146.
34. Cristaudo A, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, Chella A, Lucchi M, Mussi A, Foddis R. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma. J Thorac Oncol 2011, 6(9):1587-1593. 10.1097/JTO.0b013e31821e1c08, 21642872.
35. Mori T, Tajima K, Hirama M, Sato T, Kido K, Iwakami S, Sasaki S, Iwase A, Shiomi K, Maeda M, Hino O, Takahashi K. The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma. J Thorac Dis 2013, 5(2):145-148. 3621927, 23585940.
36. Boudville N, Paul R, Robinson BW, Creaney J. Mesothelin and kidney function-analysis of relationship and implications for mesothelioma screening. Lung Cancer 2011, 73(3):320-324. 10.1016/j.lungcan.2011.01.011, 21333373.